-
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
08 Nov 2024 15:05 GMT
… a selection marker for future clinical trials. Data highlights from the … melanoma and mesothelioma. CTX-471 has been generally well tolerated. Clinical Trial information … , including their development and clinical trial milestones such as identification of …
-
Mayo Clinic develops mesothelioma detection method
07 Nov 2024 12:15 GMT
… strategy aimed at improving mesothelioma cancer deoxyribonucleic acid (DNA … a proof-of-concept trial to identify crucial chromosomal … responses to immunotherapy in mesothelioma patients.
Moreover, their … , Exer AI, a clinical AI company collaborated with Mayo …
-
How supervised machine learning optimizes AI use in clinical trials
24 Oct 2024 12:30 GMT
… actually the MedDRA code for mesothelioma, not myocardial infarction.
ChatGPT is … sponsors and CROs meet their clinical trial objectives. Supervised ML allows greater … -based eClinical platform makes managing clinical trials simple and easy, supported by …
-
Navigating Legal Challenges: Support for California Mesothelioma Patients
31 Oct 2024 19:00 GMT
… s explore this further.
Understanding Mesothelioma
Mesothelioma, a rare but serious … experts.
Preparation for Trial: Although many mesothelioma cases settle out of … overall quality of life.
Clinical Trials: Clinical trials offer patients access to cutting …
-
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
21 Oct 2024 10:11 GMT
… non-small cell lung cancer, mesothelioma and other cancers3. Preliminary evidence … , including, without limitation: future clinical trials may not demonstrate safety and … operations, including impact on its clinical trial sites, collaborators, and contractors …
-
Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers
21 Oct 2024 10:00 GMT
… non-small cell lung cancer, mesothelioma and other cancers3. Preliminary evidence … , including, without limitation: future clinical trials may not demonstrate safety and … operations, including impact on its clinical trial sites, collaborators, and contractors …
-
Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer, Mesothelioma and Glioblastoma
29 Oct 2024 14:31 GMT
… announced the formation of its Mesothelioma Clinical Advisory Board to support the … , mesothelioma and glioblastoma; Genprex's ability to advance the clinical development … success of Genprex's clinical trials and regulatory approvals; the effect …
-
Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC)
28 Oct 2024 10:49 GMT
… pleased to expand the INTerpath clinical trial program with Moderna, evaluating … complete resection.
Malignant Pleural Mesothelioma
KEYTRUDA, in combination with … advanced or metastatic malignant pleural mesothelioma (MPM).
Classical Hodgkin Lymphoma …
-
Dr Wolf on Challenges Conducting Clinical Trials Evaluating Surgery in Mesothelioma
11 Oct 2024 21:25 GMT
… controlled trials to assess the role of surgery in mesothelioma management … explains.
Standardizing pathology interpretations in mesothelioma trials is also a challenge, Wolf … benefits of surgery from randomized clinical trials, she explains.
To address these …
-
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
14 Oct 2024 12:20 GMT
… IIIA NSCLC.
Malignant Pleural Mesothelioma
KEYTRUDA, in combination with … advanced or metastatic malignant pleural mesothelioma (MPM).
Classical Hodgkin Lymphoma … oncology. By addressing barriers to clinical trial participation, screening and treatment, …